Filing Details

Accession Number:
0001209191-23-002977
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-11 16:08:03
Reporting Period:
2023-01-10
Accepted Time:
2023-01-11 16:08:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1434316 Fate Therapeutics Inc FATE Biological Products, (No Disgnostic Substances) (2836) 651311552
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1655472 Cindy Tahl C/O Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego CA 92131
General Counsel And Secretary No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-10 11,553 $5.24 177,598 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 6,250 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, 4,503 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021, and 8,325 shares of Common Stock underlying RSUs granted to the Reporting Person on January 25, 2022. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
  2. Represents the weighted average sale price of the shares sold ranging from $5.12 to $5.36 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.